Drugs / Brilacidin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04240223 | Jan → Feb 2020 | — | Innovation Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT04784897 | Feb → Jul 2021 | COVID-19 | Innovation Pharmaceuticals, Inc. | Completed | Missed primary |
| Phase 2 | NCT02052388 | Feb → Oct 2014 | bacterial infectious disease, skin infection | Cellceutix Corporation | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02324335 Comparator | Aug 2014 → Oct 2017 | head and neck neoplasm, mucositis | Innovation Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Brilacidin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04784897 ↗ |
| Modality | Other / unclassified | “Brilacidin is a fully synthetic, non-peptidic, host defense protein mimetic” NCT04240223 ↗ |
| Route | Intravenous | “0.6mg/kg Brilacidin IV (single dose)” NCT02052388 ↗ |